Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial.
SARS-CoV-2
Xiyanping
andrographolide
coronavirus disease 2019 (COVID-19)
symptom resolution
traditional Chinese medicine
Journal
Phytotherapy research : PTR
ISSN: 1099-1573
Titre abrégé: Phytother Res
Pays: England
ID NLM: 8904486
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
revised:
17
03
2021
received:
02
11
2020
accepted:
11
04
2021
pubmed:
13
5
2021
medline:
15
9
2021
entrez:
12
5
2021
Statut:
ppublish
Résumé
Xiyanping (XYP) is a Chinese herbal medicine used in the clinic to treat respiratory infection and pneumonia. Recent evidence identified XYP as a potential inhibitor of severe acute respiratory syndrome coronavirus 2, implying XYP as a possible treatment for the coronavirus disease 2019 (COVID-19). Here, we conducted a prospective, multicenter, open-label and randomized controlled trial to evaluate the safety and effectiveness of XYP injection in patients with mild to moderate COVID-19. We consecutively recruited 130 COVID-19 patients with mild to moderate symptoms from five study sites, and randomized them in 1:1 ratio to receive XYP injection in combination with standard therapy or receive standard supportive therapy alone. We found that XYP injection significantly reduced the time to cough relief, fever resolution and virus clearance. Less patients receiving XYP injection experienced disease progression to the severe stage during the treatment process. No severe adverse events were reported during the study. Taken together, XYP injection is safe and effective in improving the recovery of patients with mild to moderate COVID-19. However, further studies are warranted to evaluate the efficacy of XYP in an expanded cohort comprising COVID-19 patients at different disease stages.
Identifiants
pubmed: 33979464
doi: 10.1002/ptr.7141
pmc: PMC8242486
doi:
Substances chimiques
Drugs, Chinese Herbal
0
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
4401-4410Subventions
Organisme : The Key Projects of Jiangxi Province
ID : 2020YBBGW0008
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Proc Soc Exp Biol Med. 1991 May;197(1):59-66
pubmed: 1708503
Adv Virol. 2015;2015:972067
pubmed: 26587022
J Biomol Struct Dyn. 2021 Jun;39(9):3092-3098
pubmed: 32329419
Phytomedicine. 2021 May;85:153242
pubmed: 33867046
Biol Pharm Bull. 2008 Nov;31(11):2018-23
pubmed: 18981566
Evid Based Complement Alternat Med. 2019 Mar 18;2019:4510591
pubmed: 31011357
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2015 Oct;32(5):1079-82
pubmed: 26964315
Int Immunopharmacol. 2012 Dec;14(4):613-9
pubmed: 23036579
Arch Virol. 2017 Mar;162(3):611-623
pubmed: 27896563
Integr Cancer Ther. 2007 Mar;6(1):66-73
pubmed: 17351028
BMJ. 2020 May 14;369:m1849
pubmed: 32409561
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
N Engl J Med. 2020 Aug 6;383(6):517-525
pubmed: 32492293
Evid Based Complement Alternat Med. 2017;2017:8248142
pubmed: 28676833
Evid Based Complement Alternat Med. 2019 Aug 29;2019:2346583
pubmed: 31558910
Immunopharmacol Immunotoxicol. 2007;29(1):81-93
pubmed: 17464769
Nat Prod Res. 2005 Apr;19(3):223-30
pubmed: 15702635
Int Immunopharmacol. 2018 Feb;55:142-150
pubmed: 29253820
Chin Med J (Engl). 2020 May 5;133(9):1087-1095
pubmed: 32358325
Zhongguo Zhong Yao Za Zhi. 2002 Feb;27(2):147-50
pubmed: 12774392
Pharmacol Res. 2020 Aug;158:104939
pubmed: 32445956
Front Pharmacol. 2020 Jul 17;11:1066
pubmed: 32848729
Zhongguo Zhong Yao Za Zhi. 2012 Sep;37(18):2792-5
pubmed: 23285936
Indian J Pharm Sci. 2014 Jan;76(1):10-8
pubmed: 24799734
Phytother Res. 2021 Aug;35(8):4401-4410
pubmed: 33979464
J Pharm Pharmacol. 2019 Feb;71(2):251-259
pubmed: 30324645
Biomed Chromatogr. 2013 Jul;27(7):825-30
pubmed: 23355108
Phytomedicine. 2021 May;85:153297
pubmed: 32798019
Pharmacogn Mag. 2016 May;12(Suppl 2):S102-8
pubmed: 27279693
Med Chem. 2011 May;7(3):237-44
pubmed: 21486208